Log in

NASDAQ:PGNYProgyny Stock Price, Forecast & News

+0.44 (+1.51 %)
(As of 08/14/2020 04:00 PM ET)
Today's Range
Now: $29.66
50-Day Range
MA: $26.57
52-Week Range
Now: $29.66
Volume356,038 shs
Average Volume783,459 shs
Market Capitalization$2.55 billion
P/E RatioN/A
Dividend YieldN/A
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption expenses for clients and their employees. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Current SymbolNASDAQ:PGNY



Sales & Book Value

Annual Sales$229.68 million
Cash Flow$0.15 per share
Book Value$1.36 per share


Net Income$-8,570,000.00


Market Cap$2.55 billion
Next Earnings Date12/2/2020 (Estimated)
OptionableNot Optionable
+0.44 (+1.51 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PGNY News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Progyny (NASDAQ:PGNY) Frequently Asked Questions

How has Progyny's stock price been impacted by COVID-19 (Coronavirus)?

Progyny's stock was trading at $22.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PGNY shares have increased by 32.9% and is now trading at $29.66.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Progyny?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Progyny

When is Progyny's next earnings date?

Progyny is scheduled to release its next quarterly earnings announcement on Wednesday, December 2nd 2020.
View our earnings forecast for Progyny

How were Progyny's earnings last quarter?

Progyny Inc (NASDAQ:PGNY) released its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.02) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.01. Progyny had a positive return on equity of 13.78% and a negative net margin of 3.81%.
View Progyny's earnings history

What guidance has Progyny issued on next quarter's earnings?

Progyny updated its FY20 earnings guidance on Wednesday, August, 5th. The company provided earnings per share guidance of $0.09-0.13 for the period, compared to the Thomson Reuters consensus estimate of $0.20. The company issued revenue guidance of $323-340 million, compared to the consensus revenue estimate of $348.15 million.

What price target have analysts set for PGNY?

8 brokerages have issued 12 month target prices for Progyny's shares. Their forecasts range from $26.00 to $44.00. On average, they anticipate Progyny's share price to reach $32.38 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for Progyny

Has Progyny been receiving favorable news coverage?

News articles about PGNY stock have been trending negative on Saturday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Progyny earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Progyny

Are investors shorting Progyny?

Progyny saw a increase in short interest in June. As of June 30th, there was short interest totaling 3,540,000 shares, an increase of 23.8% from the June 15th total of 2,860,000 shares. Based on an average daily volume of 897,400 shares, the days-to-cover ratio is presently 3.9 days. Currently, 12.4% of the shares of the company are sold short.
View Progyny's Short Interest

Who are some of Progyny's key competitors?

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), salesforce.com (CRM), Alibaba Group (BABA), Micron Technology (MU), Home Depot (HD), AbbVie (ABBV), Honeywell International (HON), Walt Disney (DIS), Marvell Technology Group (MRVL) and UnitedHealth Group (UNH).

When did Progyny IPO?

(PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

What is Progyny's stock symbol?

Progyny trades on the NASDAQ under the ticker symbol "PGNY."

Who are Progyny's major shareholders?

Progyny's stock is owned by a number of retail and institutional investors. Top institutional investors include TPG Group Holdings SBS Advisors Inc. (22.46%), Macquarie Group Ltd. (4.12%), Vanguard Group Inc. (2.93%), FMR LLC (1.28%), GW&K Investment Management LLC (0.69%) and Bamco Inc. NY (0.47%). Company insiders that own Progyny stock include Beth C Seidenberg, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Karin Ajmani, Norman Payson, Peter Anevski and Plc Glaxosmithkline.
View institutional ownership trends for Progyny

Which institutional investors are selling Progyny stock?

PGNY stock was sold by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc., Crestwood Capital Management L.P., Federated Hermes Inc., Pier Capital LLC, and Harbor Investment Advisory LLC. Company insiders that have sold Progyny company stock in the last year include Beth C Seidenberg, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Karin Ajmani, Norman Payson, Peter Anevski, and Plc Glaxosmithkline.
View insider buying and selling activity for Progyny

Which institutional investors are buying Progyny stock?

PGNY stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., FMR LLC, Macquarie Group Ltd., GW&K Investment Management LLC, Summit Partners Public Asset Management LLC, Orbimed Advisors LLC, Holocene Advisors LP, and Frontier Capital Management Co. LLC.
View insider buying and selling activity for Progyny

How do I buy shares of Progyny?

Shares of PGNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Progyny's stock price today?

One share of PGNY stock can currently be purchased for approximately $29.66.

How big of a company is Progyny?

Progyny has a market capitalization of $2.55 billion and generates $229.68 million in revenue each year. The company earns $-8,570,000.00 in net income (profit) each year or $0.11 on an earnings per share basis.

What is Progyny's official website?

The official website for Progyny is www.progyny.com.

How can I contact Progyny?

Progyny's mailing address is 1359 BROADWAY, NEW YORK NY, 10018. The company can be reached via phone at 212-888-3124 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.